Transforming patients’ lives by leading innovation in nuclear medicine

At Advanced Accelerator Applications (AAA), we are reimagining nuclear medicine and cancer care. Our mission is to transform patients’ lives by developing and delivering targeted radioligand therapies and precision imaging radioligands for oncology

Turning the power of nuclear technology into a medical force

Not your grandparents’ nuclear medicine

Wistia video thumbnail

AAA is Innovating Against Cancer

AAA is developing a pipeline of radioligand theragnostic pairings for oncology indications.

Our theragnostic radioligand platform involves radiolabeling a targeting molecule with fluorine 18 (F-18), gallium 68 (Ga-68), or other radionuclides used for precision radioligand imaging, or with lutetium 177 (Lu-177), actinium 225 (Ac-225) or other radionuclides used for treatment to create a targeted radioligand therapy.

Our other products include radiopharmaceuticals for molecular imaging with Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

Our Products

Our expertise is built on a more than 15-year legacy of manufacturing a portfolio of PET and SPECT nuclear medicine imaging products for a number of indications in oncology, neurology, cardiology and infectious & inflammatory diseases.

Looking For Clinical Trials?

As part of the development process, our investigational radioligand products are evaluated in clinical trials to find new and better ways to diagnose and treat disease.

About Advanced Accelerator Applications

+1,100

Associates globally

12

Countries

1 of the 4

platforms of the Novartis Bold4Cure strategy

Founded in 2002, AAA has a strong legacy as a pioneer in nuclear medicine.
We believe targeted radioligand therapy has the potential to be broadly used in many different tumor types.

“This is a very exciting time in AAA’s development. I believe in the potential of radioligand therapy to transform patients’ lives and I am committed to exploring this therapeutic approach in multiple tumor types.”

Sidonie Golombowski-Daffner
President of AAA

Latest news